JP2017500017A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017500017A5 JP2017500017A5 JP2016532136A JP2016532136A JP2017500017A5 JP 2017500017 A5 JP2017500017 A5 JP 2017500017A5 JP 2016532136 A JP2016532136 A JP 2016532136A JP 2016532136 A JP2016532136 A JP 2016532136A JP 2017500017 A5 JP2017500017 A5 JP 2017500017A5
- Authority
- JP
- Japan
- Prior art keywords
- culture
- cells
- liters
- item
- viable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 238000000034 method Methods 0.000 claims description 93
- 210000004027 cell Anatomy 0.000 claims description 67
- 230000001186 cumulative effect Effects 0.000 claims description 28
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 26
- 108090000623 proteins and genes Proteins 0.000 claims description 14
- 229910052742 iron Inorganic materials 0.000 claims description 13
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 claims description 11
- 238000010899 nucleation Methods 0.000 claims description 10
- 150000001413 amino acids Chemical class 0.000 claims description 9
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 8
- 229910052802 copper Inorganic materials 0.000 claims description 8
- 239000010949 copper Substances 0.000 claims description 8
- 230000010412 perfusion Effects 0.000 claims description 8
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 7
- 239000002699 waste material Substances 0.000 claims description 7
- 239000011701 zinc Substances 0.000 claims description 7
- 229910052725 zinc Inorganic materials 0.000 claims description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 claims description 5
- 108010050904 Interferons Proteins 0.000 claims description 4
- 102000014150 Interferons Human genes 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 229940079322 interferon Drugs 0.000 claims description 4
- 210000004962 mammalian cell Anatomy 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 102100023961 ADP-ribosylation factor-like protein 2-binding protein Human genes 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 108010008165 Etanercept Proteins 0.000 claims description 2
- 101000757692 Homo sapiens ADP-ribosylation factor-like protein 2-binding protein Proteins 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000934823 Homo sapiens Barttin Proteins 0.000 claims description 2
- 108010005716 Interferon beta-1a Proteins 0.000 claims description 2
- 229960002964 adalimumab Drugs 0.000 claims description 2
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 2
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 2
- 229940003504 avonex Drugs 0.000 claims description 2
- 229960000397 bevacizumab Drugs 0.000 claims description 2
- 238000005119 centrifugation Methods 0.000 claims description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 2
- 229960002806 daclizumab Drugs 0.000 claims description 2
- 229960000403 etanercept Drugs 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 102000037865 fusion proteins Human genes 0.000 claims description 2
- 108020001507 fusion proteins Proteins 0.000 claims description 2
- 229960000598 infliximab Drugs 0.000 claims description 2
- 229950005751 ocrelizumab Drugs 0.000 claims description 2
- 239000012716 precipitator Substances 0.000 claims description 2
- 229960004641 rituximab Drugs 0.000 claims description 2
- 229960000575 trastuzumab Drugs 0.000 claims description 2
- 210000003501 vero cell Anatomy 0.000 claims description 2
- 239000002738 chelating agent Substances 0.000 claims 1
- 229960003347 obinutuzumab Drugs 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361919629P | 2013-12-20 | 2013-12-20 | |
| US61/919,629 | 2013-12-20 | ||
| PCT/US2014/071701 WO2015095809A1 (en) | 2013-12-20 | 2014-12-19 | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020000268A Division JP2020054388A (ja) | 2013-12-20 | 2020-01-06 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017500017A JP2017500017A (ja) | 2017-01-05 |
| JP2017500017A5 true JP2017500017A5 (enExample) | 2018-02-08 |
Family
ID=52347449
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016532136A Withdrawn JP2017500017A (ja) | 2013-12-20 | 2014-12-19 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
| JP2020000268A Withdrawn JP2020054388A (ja) | 2013-12-20 | 2020-01-06 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
| JP2022197095A Pending JP2023022317A (ja) | 2013-12-20 | 2022-12-09 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020000268A Withdrawn JP2020054388A (ja) | 2013-12-20 | 2020-01-06 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
| JP2022197095A Pending JP2023022317A (ja) | 2013-12-20 | 2022-12-09 | 生物薬剤フェドバッチ生産能力及び生産物品質を改善するための灌流シード培養の使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (2) | US20160289633A1 (enExample) |
| EP (1) | EP3083933B1 (enExample) |
| JP (3) | JP2017500017A (enExample) |
| WO (1) | WO2015095809A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3083933B1 (en) | 2013-12-20 | 2026-01-21 | Biogen MA Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
| TWI743024B (zh) | 2014-06-06 | 2021-10-21 | 美商健臻公司 | 灌注培養方法及其用途 |
| TW202246486A (zh) * | 2014-06-09 | 2022-12-01 | 美商健臻公司 | 種子罐培養法(seed train processes)及其用途 |
| US20180312802A1 (en) * | 2015-11-02 | 2018-11-01 | Ares Trading S.A. | Methods for modulating production profiles of recombinant proteins in perfusion mode |
| CN116083345A (zh) | 2016-01-26 | 2023-05-09 | 勃林格殷格翰国际公司 | 对连续流动搅拌釜反应器细胞培养系统的连接灌注 |
| EP3504315A4 (en) | 2016-08-27 | 2020-04-15 | 3D Biotek, LLC | BIOREACTOR |
| EP3681989A1 (en) * | 2017-09-15 | 2020-07-22 | Bristol-Myers Squibb Company | Online biomass capacitance monitoring during large scale production of polypeptides of interest |
| KR20250151558A (ko) | 2017-10-06 | 2025-10-21 | 론자 리미티드 | 라만 분광법을 사용하는 세포 배양의 자동 제어 |
| CN118580928A (zh) | 2017-10-16 | 2024-09-03 | 里珍纳龙药品有限公司 | 灌注生物反应器及相关使用方法 |
| WO2019094333A1 (en) * | 2017-11-13 | 2019-05-16 | Amgen Inc. | Methods for producing protein products |
| TWI827570B (zh) * | 2017-12-11 | 2024-01-01 | 美商安進公司 | 雙特異性抗體產品之連續製造製程 |
| CN110241012B (zh) * | 2018-03-09 | 2022-11-01 | 嘉和生物药业有限公司 | 一种生物大分子上游分阶段截留的生产方法、生产模块及在生产中的应用 |
| US12365865B2 (en) * | 2018-04-29 | 2025-07-22 | Regenxbio Inc. | Scalable clarification process for recombinant AAV production |
| US12071607B2 (en) * | 2018-06-01 | 2024-08-27 | Lonza Ltd. | Midscale model for organic growth and phasing |
| WO2020086408A1 (en) | 2018-10-26 | 2020-04-30 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | A high-yield perfusion-based transient gene expression bioprocess |
| JP7453151B2 (ja) * | 2018-11-02 | 2024-03-19 | 協和キリン株式会社 | 液体培地の調製方法 |
| CA3127629A1 (en) * | 2019-01-25 | 2020-07-30 | Biogen Ma Inc. | Seed culture process for aav production |
| US20220204918A1 (en) * | 2019-04-11 | 2022-06-30 | Merck Patent Gmbh | Cell culture media comprising keto acids |
| JP7680418B2 (ja) * | 2019-07-16 | 2025-05-20 | イノベント バイオロジクス（スーチョウ）カンパニー，リミティド | 高密度連続接種の細胞培養方法及びその応用 |
| KR20220039777A (ko) * | 2019-08-01 | 2022-03-29 | 브리스톨-마이어스 스큅 컴퍼니 | 유가식 세포 배양에서 단백질 생산성을 개선시키는 방법 |
| EP4058547A1 (en) | 2019-11-15 | 2022-09-21 | Lonza Ltd. | Process and system for producing an inoculum |
| JP2023553117A (ja) * | 2020-12-08 | 2023-12-20 | パートナー セラピューティクス インコーポレイテッド | 顆粒球マクロファージコロニー刺激因子の製造 |
| JP7791210B2 (ja) | 2021-05-03 | 2025-12-23 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | スペソリマブを産生するための方法 |
| WO2023114897A2 (en) | 2021-12-15 | 2023-06-22 | Homology Medicines, Inc. | Methods and compositions for the production of adeno-associated virus |
| JP2025509328A (ja) * | 2022-03-07 | 2025-04-11 | ウルトラジェニックス ファーマシューティカル インコーポレイテッド | 改良されたバッチａａｖ産生システムおよび方法 |
| IL319171A (en) * | 2022-09-06 | 2025-04-01 | Amgen Inc | Lean cell culture perfusion methods |
Family Cites Families (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
| US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
| US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
| WO1987005330A1 (en) | 1986-03-07 | 1987-09-11 | Michel Louis Eugene Bergh | Method for enhancing glycoprotein stability |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
| EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| DE68925971T2 (de) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| JPH06508511A (ja) | 1990-07-10 | 1994-09-29 | ケンブリッジ アンティボディー テクノロジー リミティド | 特異的な結合ペアーの構成員の製造方法 |
| US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
| ATE164395T1 (de) | 1990-12-03 | 1998-04-15 | Genentech Inc | Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften |
| EP1279731B1 (en) | 1991-03-01 | 2007-05-30 | Dyax Corporation | Process for the development of binding mini-proteins |
| ES2315612T3 (es) | 1991-04-10 | 2009-04-01 | The Scripps Research Institute | Genotecas de receptores heterodimericos usando fagemidos. |
| WO1992022653A1 (en) | 1991-06-14 | 1992-12-23 | Genentech, Inc. | Method for making humanized antibodies |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| ATE408012T1 (de) | 1991-12-02 | 2008-09-15 | Medical Res Council | Herstellung von autoantikörpern auf phagenoberflächen ausgehend von antikörpersegmentbibliotheken |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| US5856179A (en) * | 1994-03-10 | 1999-01-05 | Genentech, Inc. | Polypeptide production in animal cell culture |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| EP1978033A3 (en) | 1995-04-27 | 2008-12-24 | Amgen Fremont Inc. | Human antibodies derived from immunized xenomice |
| WO1996034096A1 (en) | 1995-04-28 | 1996-10-31 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| ATE549918T1 (de) | 1996-12-03 | 2012-04-15 | Amgen Fremont Inc | Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden |
| CA2225189C (en) | 1997-03-06 | 2010-05-25 | Queen's University At Kingston | Canine factor viii gene, protein and methods of use |
| WO2002040544A2 (en) | 2000-11-14 | 2002-05-23 | Board Of Regents, University Of Texas Systems | Mutant human factor ix with an increased resistance to inhibition by heparin |
| JP4176472B2 (ja) | 2000-12-20 | 2008-11-05 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 哺乳動物細胞の種連続増殖（ｓｅｅｄ−ｔｒａｉｎｅｘｐａｎｓｉｏｎ）のための装置及び方法 |
| CA2457429A1 (en) | 2001-09-04 | 2003-03-13 | Francis J. Carr | Modified factor ix |
| PT1486785E (pt) | 2002-02-21 | 2011-05-12 | Tokyo Gas Co Ltd | Agentes de teste para avalia??o de efeito farmacol?gico de f?rmaco, e m?todo e reagentes para rastreio de f?rmaco que tem excelente efeito de administra??o e/ou pequeno efeito secund?rio de entre f?rmacos compreendendo enzimas, inibidores enzim?ticos |
| AU2004204494B2 (en) | 2003-01-09 | 2011-09-29 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| WO2004065416A2 (en) | 2003-01-16 | 2004-08-05 | Genentech, Inc. | Synthetic antibody phage libraries |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| US7348004B2 (en) | 2003-05-06 | 2008-03-25 | Syntonix Pharmaceuticals, Inc. | Immunoglobulin chimeric monomer-dimer hybrids |
| ES2456015T3 (es) * | 2004-03-05 | 2014-04-21 | Dsm Ip Assets B.V. | Procedimiento para cultivar células mediante perfusión continua y flujo tangencial alternante |
| US7294484B2 (en) | 2004-08-27 | 2007-11-13 | Wyeth Research Ireland Limited | Production of polypeptides |
| US8383388B2 (en) | 2006-06-19 | 2013-02-26 | Catalyst Biosciences, Inc. | Modified coagulation factor IX polypeptides and use thereof for treatment |
| EP2527425A1 (en) * | 2006-09-13 | 2012-11-28 | Abbott Laboratories | Cell culture improvements |
| US7700734B2 (en) | 2007-01-09 | 2010-04-20 | Shu-Wha Lin | Recombinant human factor IX and use thereof |
| CA2702363A1 (en) | 2007-10-15 | 2009-04-23 | The University Of North Carolina At Chapel Hill | Human factor ix variants with an extended half life |
| RU2010146387A (ru) | 2008-04-16 | 2012-05-27 | БАЙЕР ХЕЛСКЕР ЛЛСи (US) | Модифицированные полипептиды фактора ix и их применение |
| EP2282767A4 (en) | 2008-04-16 | 2012-07-11 | Bayer Healthcare Llc | MODIFICATION OF FACTOR IX ORIENTED SITE |
| EP2268807A2 (en) | 2008-04-21 | 2011-01-05 | Novo Nordisk A/S | Hyperglycosylated human coagulation factor ix |
| AU2009240386A1 (en) * | 2008-04-23 | 2009-10-29 | Symphogen A/S | Methods for manufacturing a polyclonal protein |
| CA2727006A1 (en) * | 2008-06-13 | 2009-12-17 | Centocor Ortho Biotech Inc. | Methods for obtaining high viable cell density in mammalian cell culture |
| WO2011069164A2 (en) | 2009-12-06 | 2011-06-09 | Biogen Idec Ma Inc. | Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof |
| AU2011207425A1 (en) * | 2010-01-25 | 2012-08-16 | Ventria Bioscience | Methods and compositions for improving protein production |
| CA2804280A1 (en) | 2010-07-09 | 2012-01-12 | Biogen Idec Hemophilia Inc. | Chimeric clotting factors |
| US9611310B2 (en) | 2010-07-09 | 2017-04-04 | Bioverativ Therapeutics Inc. | Systems for factor VIII processing and methods thereof |
| MY166954A (en) | 2010-07-09 | 2018-07-25 | Bioverativ Therapeutics Inc | Factor ix polypeptides and methods of use thereof |
| EP2686415B1 (en) | 2011-03-18 | 2017-11-15 | GE Healthcare Bio-Sciences AB | Flexible bag for cultivation of cells |
| KR20230114317A (ko) * | 2011-07-01 | 2023-08-01 | 암젠 인크 | 포유동물 세포 배양 |
| EP3083933B1 (en) | 2013-12-20 | 2026-01-21 | Biogen MA Inc. | Use of perfusion seed cultures to improve biopharmaceutical fed-batch production capacity and product quality |
-
2014
- 2014-12-19 EP EP14827357.6A patent/EP3083933B1/en active Active
- 2014-12-19 US US15/038,698 patent/US20160289633A1/en not_active Abandoned
- 2014-12-19 WO PCT/US2014/071701 patent/WO2015095809A1/en not_active Ceased
- 2014-12-19 JP JP2016532136A patent/JP2017500017A/ja not_active Withdrawn
-
2020
- 2020-01-06 JP JP2020000268A patent/JP2020054388A/ja not_active Withdrawn
-
2022
- 2022-12-09 JP JP2022197095A patent/JP2023022317A/ja active Pending
-
2025
- 2025-01-17 US US19/027,281 patent/US20250382568A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017500017A5 (enExample) | ||
| KR101644954B1 (ko) | 배양 동안 락테이트의 축적을 감소시키는 방법 및 폴리펩타이드를 생산하는 방법 | |
| US11912739B2 (en) | Sterile chromatography and manufacturing processes | |
| US12480947B2 (en) | Method for generating high affinity antibodies | |
| KR101591671B1 (ko) | 항체의 이질성을 감소시키는 방법 및 그 항체의 제조방법 | |
| US9908932B2 (en) | Methods of shifting an isoelectric profile of a protein product and uses thereof | |
| CN104245922B (zh) | 絮凝方法 | |
| SI2904092T1 (en) | Ingredients and procedures for the production of glycoproteins | |
| JP2019514417A (ja) | グルタミンシンセターゼ遺伝子内相補ベクターを用いた高レベルのヘテロマータンパク質発現細胞の直接選択 | |
| JP2015532096A5 (enExample) | ||
| RU2017101195A (ru) | Способы культивирования клеток и среды, предусматривающие n-ацетилцистеин | |
| CN105378071A (zh) | 用于产生稳定转染细胞的方法和组合物 | |
| JP6108170B2 (ja) | 細胞培養用培地 | |
| HRP20250491T1 (hr) | Upotreba monensina za regulaciju glikozilacije rekombinantnih proteina | |
| US20160108357A1 (en) | Methods of culturing a cell | |
| JP3020300B2 (ja) | 動物細胞培養用組成物、培養方法および生理活性物質の製造法 | |
| CN104854125A (zh) | 在不存在全能核酸酶的情况下分离synagis*的方法 | |
| Aalilouch et al. | Monoclonal antibody production using hybridoma technology: advances, challenges and applications | |
| KR20200083564A (ko) | 단백질 산물을 제조하는 방법 | |
| Pörtner et al. | Cell culture technology | |
| AU2017393059B2 (en) | Method for producing corneal epithelial cell mass | |
| RU2786078C2 (ru) | Способы стерильной хроматографии и производства | |
| Bodeus et al. | In Vitro Production of Rat Monoclonal Antibodies | |
| US11254964B1 (en) | Cell culture methods for increased cell viability | |
| CN120137879A (zh) | 一种高效率正确表达具有非对称结构抗体的细胞培养方法 |